The Japanese Ministry of Health, Labor and Welfare’s Pharmaceuticals and Medical Devices Agency has approved Merck’s (NYSE:MRK) Keytruda (pembrolizumab) for patients with PD-L1-positive resectable, advanced or recurrent esophageal squamous cell carcinoma who have progressed after chemo.
The regulator also approved a new dosing regimen for the PD-1 inhibitor, 400 mg every six weeks as an intravenous infusion over 30 minutes across all adult indications (original regimen, still available, is 200 mg every three weeks).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.